New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Merck (MRK) Receives FDA Apprval of EMEND sNDA
September 2, 2015 8:05 AM EDTMerck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for EMEND® (aprepitant) capsules, a substance P/neurokinin 1 (NK1) receptor antagonist. With this expanded indication, EMEND capsules are now approved for use in combination with other antiemetic agents in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg (approximately 66 pounds) for the prevention of acute and... More
Merck (MRK) Offers Additional analyses from IMPROVE-IT
September 1, 2015 9:06 AM EDTMerck (NYSE: MRK) announced results from new analyses from the IMPROVE-IT study.
IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe (VYTORIN) and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions, said Dr. Michael A. Blazing, Duke Department of Medicine.
VYTORIN (ezetimibe and simvastatin) and ZETIA (ezetimibe) are... More
